Mod GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-19. Numbers and descriptions here follow the published literature rather than marketing material.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Assessed by visual inspection under ordinary light |
| Primary analytical method | Reversed-phase liquid chromatography | Purity estimated from peak area at 214 nm |
| Confirmatory method | Mass spectrometry | Observed mass compared with calculated value |
| Powder storage temperature | Minus 20 degrees Celsius | Minus 80 for extended archival periods |
| Solution stability | Hours to days at 2 to 8 degrees Celsius | Influenced by pH, buffer, and concentration |
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
=== Hydrogen nuclear magnetic resonance === Hydrogen nuclear magnetic resonance (2HNMR) is a technique that uses an external magnetic field and deuterium to replace the ordinary form of hydrogen. The ordinary form of hydrogen refers to the elemental form of hydrogen with a molecular weight of approximately 1 g/mol. It contains only one proton and has no neutrons. Deuterium is the isotope form of hydrogen which has a heavier mass compared to ordinary hydrogen. It contains one proton and neutron and has a molecular weight of approximately 2 g/mol. This technique can be used to investigate motions of acyl chains in lipids. It measures carbon and deuterium interactions and the mobility of these interactions within various regions of the lipid and also determines order parameters. The process involves using quadrupole signaling properties for examining lamellar versus non–lamellar phases as well. An external magnetic field monitors the alignment of paramagnetic compounds and uses changes in the positive or negative magnetic spin values to detect these changes.
==== Operation Safe Veracruz ==== In response to the multiple executions between the drug cartels, the federal government launched a military-led operation in the state of Veracruz, known in Spanish as Operativo Veracruz Seguro. In October 2011, the state of Veracruz was a disputed territory between Los Zetas and the Gulf Cartel and Sinaloa Cartel. Francisco Blake Mora, Secretary of the Interior at the time, said that the operation was implemented to serve the following goals:
== Detecting peptides == Typically, peptide signals are detected at the MS1 level and distinguished from chemical noise through their characteristic isotopic pattern. These patterns are then tracked across the retention time dimension and used to reconstruct a chromatographic elution profile of the mono-isotopic peptide mass. The total ion current of the peptide signal is then integrated and used as a quantitative measurement of the original peptide concentration. For each detected peptide, all isotopic peaks are first found and the charge state is then assigned. Label-free quantification may be based on precursor signal intensity and has problems due to isolation interference: in high-throughput studies, the identity of the peptide precursor ion being measured could easily be a completely different peptide with a similar m/z ratio and which elutes in a time frame overlapping with that of the former peptide. Spectral counting has problems due to the fact that the peptides are identified, thus making it necessary to run an additional MS/MS scan which takes time and therefore reduces the resolution of the experiment.
=== Mechanism of action === Levobunolol is a non-cardioselective beta blocker, that is, it blocks beta-1 receptors as well as beta-2 receptors. The latter type dominates in the ciliary body, where it controls aqueous humour production. Blocking this type of receptor reduces aqueous humour production, lowering intraocular pressure. The substance has no relevant membrane stabilizing effect or intrinsic sympathomimetic activity. Like other beta blockers, and unlike the anti-glaucoma medication pilocarpine, levobunolol has no effect on accommodation and pupil size.
Sources: en.wikipedia.org
== Research misconduct == In September 2024, Masliah's work came under intense scrutiny when an investigation led by the journal Science exposed extensive image manipulation across 132 of his published research papers. A 286-page dossier compiled by forensic analysts and neuroscientists pointed to repeated instances of Western blot manipulation, image reuse, and other forms of digital editing across decades of his research. These allegations involved crucial studies related to Alzheimer's and Parkinson's disease, particularly surrounding the alpha-synuclein protein. The dossier was sent to the HHS Office of Research Integrity, which requested that the National Institute on Aging (NIA) start a research misconduct investigation in May 2023. The NIA started their investigation in December 2023. In September 2024, the NIH confirmed that Masliah was no longer leading the Division of Neuroscience at the NIA, following the conclusion of their investigation. The controversy includes papers that have influenced clinical trials and investment decisions in the pharmaceutical industry. 238 active patents cite papers by Masliah that contain anomalous images and data. A notable impact on the pharmaceutical industry concerns the experimental Parkinson's drug prasinezumab, developed by Prothena Biosciences in collaboration with Roche. A Phase II study reported in August 2022 found no statistically significant effect from the drug vs placebo on measures of Parkinson's disease progression. Several papers foundational to the development of prasinezumab were flagged for image manipulation.
=== Color rendering === The spectrum of light produced by an incandescent lamp closely approximates that of a black body radiator at the same temperature. The basis for light sources used as the standard for color perception is a tungsten incandescent lamp operating at a defined temperature.
The charge alleges that Viñas Alonso attempted to exchange $100 on the black market, and came after a tip-off by an anonymous informant. Advocates of Viñas Alonso said that if he had exchanged that money, he only intended to use it to buy food and supplies for the Llansó retirement home, which was again facing a food shortage. Viñas Alonso later wrote on Facebook that the money, which had agreed to be converted by a unanimous vote of the Board of Trustees at the Llansó retirement home, was made an at unofficial exchange rate of $MN378 for US$100, instead of the government-mandated exchange rate of $MN120. He said that there had been two such occasions of unofficial market exchange, and technically that does constitute an economic crime in Cuba, but that people are rarely prosecuted for such a low sum of money. He was then issued a work-from-home order, and restricted from leaving Cuba.
Sources: en.wikipedia.org
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.
Dry powder is markedly more stable than solution and is usually held frozen and desiccated. Room temperature exposure over days degrades it more slowly than most people assume, but long-term integrity favors freezer storage. Light protection is recommended regardless of temperature.
Methods, columns, gradients, and detection wavelengths are not standardized across laboratories. Some figures describe only the main peak area at one wavelength and ignore water, salts, or counter-ions. Without stated conditions, comparing reported percentages across sources is unreliable.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.